NovaBridge Schedules March 9 Call to Review Phase 2a VIS-101 Data
NovaBridge will host a virtual call on March 9, 2026 at 9:00 AM ET to discuss Phase 2a data for VIS-101 in wet AMD patients. Visara, majority-owned by NovaBridge, holds global development and commercialization rights for VIS-101 outside Greater China and certain Asian territories.
1. Business Update Call Scheduled
NovaBridge has announced a virtual business update call on Monday, March 9, 2026 at 9:00 AM ET. The event will feature presentations by NovaBridge CEO Sean Fu, Visara Executive Chairman Emmett T. Cunningham Jr., and Visara Chief Medical Officer Cadmus Rich.
2. VIS-101 Phase 2a Study Overview
VIS-101 is a bispecific, tetravalent inhibitor targeting VEGF-A and ANG-2 designed for wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. The ongoing randomized, dose-ranging Phase 2a trial aims to evaluate efficacy and durability compared with current standards of care.
3. Visara Subsidiary Rights and Commercialization
Visara, a majority-owned subsidiary of NovaBridge, holds global development and commercialization rights to VIS-101 outside Greater China and specified Asian territories. Everest Medicines retains rights within those Asian markets under license from Visara.